NDA 012093 · Bausch
Isordil
Isosorbide Dinitrate · Oral · Nitrate Vasodilator
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jan 14, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1959
Nov 9, 1959
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
84
17 Phase 3, 4 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Isosorbide Dinitrate" as an intervention, any sponsor and status, largest first.
- Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)Pivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07252544 · 3,156 participants (planned) · Start Dec 1, 2025 · Primary completion Aug 31, 2027
Drug: Isosorbide Mononitrate; Butylphthalide and 2 more · For: Stroke, Lacunar; Stroke, Acute Ischemic; Cerebral Small Vessel Diseases
- Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP PreventionPivotal-lookingStatus unknown
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT04425993 · 2,700 participants · Start Jul 1, 2020 · Primary completion May 30, 2022
Drug: Isosorbide Dinitrate 5 MG; Indomethacin 100 MG and 2 more · For: Post-ERCP Acute Pancreatitis
Sites: Xiamen, China; Lanzhou, China; Xi'an, China · 4 sites in all
- Intensive Arterial Pressure Control in Acute Coronary SyndromePivotal-lookingCompleted
University of MonastirAcademic, hospital or other
NCT02135315 · 1,500 participants · Start Mar 2014 · Primary completion Dec 31, 2020
Drug: Isosorbide Dinitrate · For: Acute Coronary Syndrome
Sites: Monastir, Tunisia
- Nicardipine to Avoid Spasm in Trans Radial Percutaneous Coronary InterventionPivotal-lookingCompleted
Pr. Semir NouiraAcademic, hospital or other
NCT04538534 · 1,500 participants · Start Nov 1, 2020 · Primary completion Feb 1, 2022
Drug: Nicardipine · For: Spasm Artery
Sites: Monastir, Tunisia
- Reduction of Cesareans by Nitric Oxide (NO) Donors in Post Term PregnanciesPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT00930618 · 1,409 participants · Start Jun 2009 · Primary completion Dec 2013
Drug: IMN; Placebo · For: Prolonged Pregnancy; Nulliparity
Sites: Paris, France
- DANHEART (H-HeFT and Met-HeFT)Pivotal-lookingCompleted
Henrik WiggersAcademic, hospital or other
NCT03514108 · 1,100 participants · Start Mar 1, 2018 · Primary completion Dec 31, 2025
Drug: Hydralazine Isosorbide Dinitrate; Placebo Oral Tablet and 2 more · For: Heart Failure; Diabetes
Sites: Holbæk, Denmark; Aabenraa, Denmark; Aalborg, Denmark · 26 sites in all
- African-American Heart Failure TrialPivotal-lookingCompleted
NitromedIndustry
NCT00047775 · 1,100 participants · Start May 2001
Drug: BiDil · For: Congestive Heart Failure
Sites: Birmingham, Alabama; Little Rock, Arkansas; Washington D.C., District of Columbia · 7 sites in all
- Baroreflex Activation Therapy for Heart FailurePivotal-lookingCompleted
CVRx, Inc.Industry
NCT02627196 · 1,090 participants · Start Apr 19, 2016 · Primary completion Oct 2023
Drug: Medical Management · For: Heart Failure
Sites: Chandler, Arizona; Mesa, Arizona; Phoenix, Arizona · 92 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Isordil (Isosorbide Dinitrate)
2024 spending
$62K
Beneficiaries
n/a
24 claims
Per beneficiary
n/a
$21.28 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,144,565 |
| 2021 | $222,286 |
| 2022 | $118,246 |
| 2023 | $68,414 |
| 2024 | $62,363 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction.
Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. · JACC Heart Fail 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Prevention of Preterm Labor by Isosorbide Dinitrate and Nitroglycerin Patch.
Ghafarzadeh M, Shakarami A, Yari F · Cardiovasc Hematol Disord Drug Targets 2023 · Randomized Controlled Trial
- Chinese herbal medicine suxiao jiuxin wan for angina pectoris.
Duan X, Zhou L, Wu T, et al. · Cochrane Database Syst Rev 2008 · Meta-Analysis, Systematic Review
- Plasma norepinephrine and mortality.
Cohn JN · Clin Cardiol 1995 · Clinical Trial, Multicenter Study
- The use of isosorbide in the treatment of severe, uncontrolled hypertension.
Fontanet H, García JC, del Río J, et al. · Arch Intern Med 1987 · Clinical Trial, Comparative Study
- Fissurectomy combined with botulinum toxin A injection for medically resistant chronic anal fissures.
Witte ME, Klaase JM, Koop R · Colorectal Dis 2010 · Comparative Study, Randomized Controlled Trial
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.